Abstract: The present disclosure provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

Abstract: Disclosed herein are improved methods for production of 2-phenylethanol by microbial fermentation of substrates comprising carbon monoxide and/or carbon dioxide and further disclosed are genetically modified microorganisms for use in such methods that alleviate dependence on natural and petrochemical processes.

Abstract: The invention relates to a method of preventing or treating pathogenic bacterial infectious diseases by providing a pharmaceutical composition comprising a LysSAP26 protein, wherein the LysSAP26 protein is a recombinant protein composed of an amino acid sequence derived from the bacteriophage genome and has the amino acid sequence set forth in SEQ ID NO: 1 as an active ingredient, and administering the pharmaceutical composition to a subject.

Abstract: Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.

Abstract: The present disclosure relates to chemo-enzymatic processes for the preparation of lactones (including, e.g., macrolactones, ?-lactones, and ?-lactones) and/or macrocyclic ketones, which are compounds of industrial value, for example, for use as fragrance ingredients. The chemo-enzymatic processes combine the in vivo microbial production of fatty acid derivatives and the subsequent ex vivo synthetic transformation of the fatty acid derivatives to provide the lactones and macrocyclic ketones.

Abstract: Disclosed is a proteomic reactor, comprising a pipette tip, an ion exchange resin filler and a solid-phase extraction membrane. The solid-phase extraction membrane is filled into the lower end of the pipette tip, and the ion exchange resin is filled into the lower end of the pipette tip and is located above the solid-phase extraction membrane. The ion exchange resin is a strong cation exchange resin or a strong anion exchange resin. Disclosed is a protein chromatographic separation platform comprising the proteomic reactor and a liquid chromatography-mass spectrometer. Disclosed is the use of the proteomic reactor and protein chromatographic separation platform in the protein identification and protein quantitative analysis of a cell, a tissue or a blood sample.

Abstract: The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.

Abstract: The present invention is based, in part, on the discovery of the human-specific regulatory control of cGAS and the structure of the active human cGAS-DNA complex, as well as compositions comprising the modified hcGAS polypeptide, hcGAS-DNA complex, hcGAS-DNA-ATP complex, and methods of screening for modulators of the structure, expression, and/or activity of such polypeptides and complexes.

Abstract: A method of conducting oxidation in an inflatable bag bioreactor or a batch reactor is provided. The inflatable bag bioreactor or the batch reactor is used as an efficient, economical, and convenient reaction vessel. The inflatable bag bioreactor or batch reactor is rotated or rocked during the reaction to ensure continued exposure of the reaction mixture to the headspace gas in the vessel. The ability of the inflatable bag to expand or contract as the volume of the contents changes helps maintain consistent pressure and avoids the need to replenish the headspace gas.

Abstract: The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

Abstract: The present invention provides for novel protic ionic liquids (PIL) or phosphate-based ionic liquid (PBIL) useful for lignocellulosic processing described herein. The novel protic ionic liquids are capable of pretreatment of lignocellulosic biomass over a wide range of pH.

Abstract: The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.

Abstract: The present invention relates to a stable C1-esterase-inhibitor (C1-Inh) preparation, which is liquid or lyophilised, characterised by a histidine content of 5-400 mM but does not contain citrate or phosphate. It further relates to a kit including the C1-Inh preparation.

Abstract: The present invention includes a method of preserving cannabinoid concentration in a biomass comprising: providing a hemp biomass in an aqueous solution; adding a culture of a cannabinoid preserving Bacillus bacteria to the hemp biomass solution; and culturing the hemp biomass with the Bacillus bacteria under conditions in which the cannabinoid concentration is maintained.

Abstract: [Problem] To provide: a novel enzyme which is derived from a microorganism other than Bacillus circulans and is highly selective for galactotrisaccharide production and with which the galactooligosaccharide can be highly efficiently produced; and a novel method capable of producing the galactooligosaccharide. [Solution] A method for producing a galatooligosaccharide, the method including bringing an enzyme having an amino acid sequence selected from the group consisting of (a) to (f) and cells of a bacterium belonging to the genus Paenibacillus and/or a galactooligosaccharide-producing enzyme for the bacterium, into contact with lactose. (a) An amino acid sequence of sequence number 1. (b) An amino acid sequence of sequence number 2. (c) An amino acid sequence of an enzyme having galactooligosaccharide-producing activity, the amino acid sequence being the amino acid sequence of sequence number 1 in which one to ten amino acids have been replaced, removed, or inserted.

Abstract: The present invention provides a method for producing a basic L-amino acid, for example, L-ornithine L-citrulline, L-arginine, L-histidine, and L-lysine by fermentation using a bacterium belonging to the family Enterobacteriaceae which has been modified to overexpress a gene encoding a protein having L-methionine/branched chain amino acid exporter activity.

Abstract: The present invention provides a composition comprising an isolated polypeptide having non-specific nuclease (NSN) activity for degrading nucleic acids comprising or consisting of at least 70% amino acid sequence identity to SEQ ID NO:2, wherein said polypeptide has NSN activity in a solution of about 4° C., and a cation complexing agent such as EDTA. Said composition may have preferentially a neutral to basic pH. A kit comprising said composition and a method using said composition are also disclosed.

Abstract: ABC multidrug transporters are key players in cancer multidrug resistance and in general xenobiotic elimination, thus their functional assays provide important tools for research and diagnostic applications. It has been found that in cells expressing functional ABCG2, ABCB1, or ABCC1 transporters, cellular PG fluorescence is strongly reduced. The invention relates to methods and uses of fluorescein derivative ester compounds of formula Ia which are analogs of PG for assessing ABC transporter activity of ABC multidrug transporters. The present accumulation assay is a novel tool for the parallel determination of the function of the multidrug transporters, in particular ABCG2, ABCB1, and ABCC1. The assay is applicable for diagnostic purposes and also allows the selection, separation and culturing of selected cell populations expressing such transporters.

Abstract: The present invention provides a method for producing a target substance, the biosynthetic pathway of which is ATP-dependent, for example, amino acids, nucleosides, nucleotides, isoprenoids, and peptides, by fermentation of a bacterium which has been modified to overexpress a gene encoding a protein having H+-translocating membrane-bound pyrophosphatase activity, for example, the hppA gene native to R. rubrum or a variant thereof.

Abstract: The present disclosure relates to systems, methods and compositions provided herein that include a compound protease. The compound protease can contain a protease domain, a cut site for another enzyme and an association domain. In some embodiments, the compound protease is part of a protein circuit.